ABBOTT BIOTHERAPEUTICS CORP 8-K 2010
Washington, D.C. 20549
Date of report (date of earliest event reported): February 23, 2010
Facet Biotech Corporation
(Exact name of registrant as specified in its charter)
1500 Seaport Boulevard
Registrants telephone number, including area code: (650) 454-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On February 23, 2010, Facet Biotech Corporation issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2009 (the Earnings Release) and conducted a webcast conference call regarding these financial results (the Webcast). The Earnings Release and transcript of the Webcast are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this current report on Form 8-K and are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.